The Munich partner site contributes to the DZKJ through its expertise in immune and metabolic system research. It focuses on identifying genetic factors that lead to disease, developing precision diagnostic methods, and advancing cell and gene therapy strategies. Research into rare diseases is being harnessed to redefine our understanding of common diseases and to develop curative treatments for conditions once considered incurable.

Scientists at the Munich site use advanced technology platforms for precise biomarker identification, AI-driven analytics, and the study of disease mechanisms in vitro and in vivo, including transgenic animal models. These resources also support the development of innovative cell and gene therapies for pediatric patients. The partner site is committed to fostering early-career scientists, enhancing patient engagement, and collaborating with the German Center for Mental Health (DZPG) and other German Centers for Health Research.